Adma Biologics Stock Performance
| ADMA Stock | USD 18.43 0.52 2.90% |
The firm shows a Beta (market volatility) of 0.54, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, ADMA Biologics' returns are expected to increase less than the market. However, during the bear market, the loss of holding ADMA Biologics is expected to be smaller as well. At this point, ADMA Biologics has a negative expected return of -5.0E-4%. Please make sure to confirm ADMA Biologics' potential upside, daily balance of power, and the relationship between the maximum drawdown and kurtosis , to decide if ADMA Biologics performance from the past will be repeated in the future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days ADMA Biologics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong primary indicators, ADMA Biologics is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors. ...more
Actual Historical Performance (%)
One Day Return 2.9 | Five Day Return 10.49 | Year To Date Return 2.56 | Ten Year Return 130.66 | All Time Return 115.56 |
1 | Disposition of 28763 shares by Adam Grossman of ADMA Biologics at 6.16 subject to Rule 16b-3 | 12/27/2024 |
2 | Insider Trading | 01/02/2025 |
3 | Adma Biologics Rises Higher Than Market Key Facts | 01/22/2025 |
4 | ADMA Biologics Gears Up to Report Q4 Earnings Whats in the Cards | 02/19/2025 |
5 | Disposition of 1855 shares by Kestenberg-messina Kaitlin M. of ADMA Biologics at 15.44 subject to Rule 16b-3 | 02/27/2025 |
6 | ADMA Biologics Inc Q4 2024 Everything You Need To Know Ahead Of Earnings | 02/28/2025 |
7 | ADMA Biologics Inc Surpasses Q4 Revenue Estimates with 117. ... | 03/03/2025 |
8 | Q4 2024 ADMA Biologics Inc Earnings Call Transcript | 03/04/2025 |
9 | Disposition of 8881 shares by Kestenberg-messina Kaitlin M. of ADMA Biologics at 16.91 subject to Rule 16b-3 | 03/06/2025 |
10 | Disposition of 55000 shares by Adam Grossman of ADMA Biologics at 5.0 subject to Rule 16b-3 | 03/07/2025 |
11 | Adma Biologics Recently Broke Out Above the 50-Day Moving Average | 03/12/2025 |
12 | Will ADMA Biologics Stock Continue Its Momentum in 2025 | 03/14/2025 |
| Begin Period Cash Flow | 86.5 M |
ADMA |
ADMA Biologics Relative Risk vs. Return Landscape
If you would invest 1,898 in ADMA Biologics on December 16, 2024 and sell it today you would lose (55.00) from holding ADMA Biologics or give up 2.9% of portfolio value over 90 days. ADMA Biologics is currently does not generate positive expected returns and assumes 3.0985% risk (volatility on return distribution) over the 90 days horizon. In different words, 27% of stocks are less volatile than ADMA, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
ADMA Biologics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for ADMA Biologics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as ADMA Biologics, and traders can use it to determine the average amount a ADMA Biologics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -2.0E-4
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ADMA |
Estimated Market Risk
| 3.1 actual daily | 27 73% of assets are more volatile |
Expected Return
| 0.0 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.0 actual daily | 0 Most of other assets perform better |
Based on monthly moving average ADMA Biologics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of ADMA Biologics by adding ADMA Biologics to a well-diversified portfolio.
ADMA Biologics Fundamentals Growth
ADMA Stock prices reflect investors' perceptions of the future prospects and financial health of ADMA Biologics, and ADMA Biologics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on ADMA Stock performance.
| Return On Equity | 0.82 | ||||
| Return On Asset | 0.21 | ||||
| Profit Margin | 0.46 % | ||||
| Operating Margin | 0.33 % | ||||
| Current Valuation | 4.34 B | ||||
| Shares Outstanding | 236.62 M | ||||
| Price To Earning | (1.55) X | ||||
| Price To Book | 12.50 X | ||||
| Price To Sales | 10.23 X | ||||
| Revenue | 426.45 M | ||||
| Gross Profit | 219.55 M | ||||
| EBITDA | 138.98 M | ||||
| Net Income | (28.24 M) | ||||
| Cash And Equivalents | 52.42 M | ||||
| Cash Per Share | 0.27 X | ||||
| Total Debt | 141.42 M | ||||
| Debt To Equity | 1.32 % | ||||
| Current Ratio | 7.94 X | ||||
| Book Value Per Share | 1.48 X | ||||
| Cash Flow From Operations | 8.8 M | ||||
| Earnings Per Share | 0.81 X | ||||
| Market Capitalization | 4.36 B | ||||
| Total Asset | 329.18 M | ||||
| Retained Earnings | (506.26 M) | ||||
| Working Capital | 207.21 M | ||||
| Current Asset | 21.29 M | ||||
| Current Liabilities | 4.22 M | ||||
About ADMA Biologics Performance
By analyzing ADMA Biologics' fundamental ratios, stakeholders can gain valuable insights into ADMA Biologics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if ADMA Biologics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if ADMA Biologics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.08) | (0.08) | |
| Days Of Inventory On Hand | 335.55 | 298.54 | |
| Return On Capital Employed | 0.09 | 0.08 | |
| Return On Assets | (0.08) | (0.08) | |
| Return On Equity | (0.24) | (0.23) |
Things to note about ADMA Biologics performance evaluation
Checking the ongoing alerts about ADMA Biologics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for ADMA Biologics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| ADMA Biologics generated a negative expected return over the last 90 days | |
| ADMA Biologics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 426.45 M. Net Loss for the year was (28.24 M) with profit before overhead, payroll, taxes, and interest of 219.55 M. | |
| ADMA Biologics has a poor financial position based on the latest SEC disclosures | |
| Over 89.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from zacks.com: Will ADMA Biologics Stock Continue Its Momentum in 2025 |
- Analyzing ADMA Biologics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether ADMA Biologics' stock is overvalued or undervalued compared to its peers.
- Examining ADMA Biologics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating ADMA Biologics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of ADMA Biologics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of ADMA Biologics' stock. These opinions can provide insight into ADMA Biologics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for ADMA Stock analysis
When running ADMA Biologics' price analysis, check to measure ADMA Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADMA Biologics is operating at the current time. Most of ADMA Biologics' value examination focuses on studying past and present price action to predict the probability of ADMA Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ADMA Biologics' price. Additionally, you may evaluate how the addition of ADMA Biologics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |